- Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
- April 29, 2025
- Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- April 26, 2025
- Pfizer Announces 2025 Shareholder Meeting Preliminary Results
- April 24, 2025
- Pfizer Declares Second-Quarter 2025 Dividend
- April 23, 2025
- Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
- April 23, 2025
- ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
- April 16, 2025
- Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
- April 14, 2025
- Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
- April 10, 2025
- European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
- April 01, 2025
- Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
- March 18, 2025
- Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
- March 11, 2025
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- February 24, 2025
- Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
- February 13, 2025
- U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- February 12, 2025
- Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
- February 10, 2025
- Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
- February 04, 2025
- Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
- February 03, 2025
- Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
- January 28, 2025
- Pfizer's BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- January 25, 2025
- Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-NaÏve, High-Risk Non-Muscle Invasive Bladder Cancer
- January 10, 2025
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- January 06, 2025
- U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
- December 20, 2024
- Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
- December 19, 2024
- Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
- December 17, 2024
- Pfizer Declares First-Quarter 2025 Dividend
- December 12, 2024
- Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
- December 12, 2024
- Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
- December 10, 2024
- Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
- December 10, 2024
- Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
- December 05, 2024